Vascular risk profile and changes of arterial hypertension after surgical revascularization in adult Moyamoya patients.
Arterial hypertension
Cerebral revascularization
Moyamoya
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
29 May 2024
29 May 2024
Historique:
received:
13
12
2023
accepted:
13
05
2024
medline:
30
5
2024
pubmed:
30
5
2024
entrez:
29
5
2024
Statut:
epublish
Résumé
Moyamoya disease (MMD) is a rare stenoocclusive cerebral vasculopathy often treated by neurosurgical revascularization using extracranial-intracranial bypasses to prevent ischemic or hemorrhagic events. Little is known about the vascular risk profile of adult MMD patients compared to the general population. We therefore analyzed 133 adult MMD patients and compared them with data from more than 22,000 patients from the German Health Update database. Patients with MMD showed an age- and sex-adjusted increased prevalence of arterial hypertension, especially in women between 30 and 44 years and in patients of both sexes between 45 and 64 years. Diabetes mellitus was diagnosed significantly more frequently in MMD patients with increasing age, whereas the vascular risk profile in terms of obesity, nicotine and alcohol consumption was similar to that of the general population. Antihypertensive medication was changed one year after surgical revascularization in 67.5% of patients with a tendency towards dose reduction in 43.2% of all patients. After revascularization, physicians need to be aware of a high likelihood of changes in arterial hypertension and should adjust all other modifiable systemic vascular risk factors to achieve the best treatment possible.
Identifiants
pubmed: 38811635
doi: 10.1038/s41598-024-61966-8
pii: 10.1038/s41598-024-61966-8
doi:
Substances chimiques
Antihypertensive Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
12364Informations de copyright
© 2024. The Author(s).
Références
Kamada, F. et al. A genome-wide association study identifies RNF213 as the first Moyamoya disease gene. J. Hum. Genet. 56(1), 34–40. https://doi.org/10.1038/jhg.2010.132 (2011).
doi: 10.1038/jhg.2010.132
pubmed: 21048783
Bersano, A. et al. European Stroke Organisation (ESO) Guidelines on Moyamoya angiopathy Endorsed by Vascular European Reference Network (VASCERN). Eur. Stroke J. 8(1), 55–84. https://doi.org/10.1177/23969873221144089 (2023).
doi: 10.1177/23969873221144089
pubmed: 37021176
pmcid: 10069176
Kraemer, M. et al. Clinical presentation of Moyamoya angiopathy in Europeans: Experiences from Germany with 200 patients. J. Neurol. 266(6), 1421–1428. https://doi.org/10.1007/s00415-019-09277-1 (2019).
doi: 10.1007/s00415-019-09277-1
pubmed: 30868219
Acker, G. et al. Distinct clinical and radiographic characteristics of moyamoya disease amongst European Caucasians. Eur. J. Neurol. 22(6), 1012–1017. https://doi.org/10.1111/ene.12702 (2015).
doi: 10.1111/ene.12702
pubmed: 25847099
Fujimura, M. et al. 2021 Japanese guidelines for the management of Moyamoya disease: Guidelines from the research committee on Moyamoya disease and Japan stroke society. Neurologia medico-chirurgica. 62(4), 165–170. https://doi.org/10.2176/jns-nmc.2021-0382 (2022).
doi: 10.2176/jns-nmc.2021-0382
pubmed: 35197402
pmcid: 9093674
Williams, B. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur. Heart J. 39(33), 3021–3104. https://doi.org/10.1093/eurheartj/ehy339 (2018).
doi: 10.1093/eurheartj/ehy339
pubmed: 30165516
Suzuki, J. & Takaku, A. Cerebrovascular, “moyamoya” disease: Disease showing abnormal net-like vessels in base of brain. Arch. Neurol. 20(3), 288–299. https://doi.org/10.1001/archneur.1969.00480090076012 (1969).
doi: 10.1001/archneur.1969.00480090076012
pubmed: 5775283
Neuhauser, H., Kuhnert, R. & Born, S. 12-Month prevalence of hypertension in Germany (2017).
Heidemann, C., Kuhnert, R., Born, S. & Scheidt-Nave, C. 12-Month prevalence of known diabetes mellitus in Germany (2017).
Schienkiewitz, A., Kuhnert, R., Blume, M. & Mensink, G. Übergewicht und Adipositas bei Erwachsenen in Deutschland-Ergebnisse der Studie GEDA 2019/2020-EHIS (2022).
Starker, A., Kuhnert, R., Hoebel, J. & Richter, A. Rauchverhalten und Passivrauchbelastung Erwachsener–Ergebnisse aus GEDA 2019/2020-EHIS (2022).
Sutton, C. X. Y. et al. Identification of associations and distinguishing moyamoya disease from ischemic strokes of other etiologies: A retrospective case-control study. Ann. Med. Surg. 2022(78), 103771. https://doi.org/10.1016/j.amsu.2022.103771 (2012).
doi: 10.1016/j.amsu.2022.103771
Lei, C., Wu, B., Ma, Z., Zhang, S. & Liu, M. Association of moyamoya disease with thyroid autoantibodies and thyroid function: A case-control study and meta-analysis. Eur. J. Neurol. 21(7), 996–1001. https://doi.org/10.1111/ene.12425 (2014).
doi: 10.1111/ene.12425
pubmed: 24684272
Ge, P. et al. Modifiable risk factors associated with moyamoya disease: A case-control study. Stroke. 51(8), 2472–2479 (2020).
doi: 10.1161/STROKEAHA.120.030027
pubmed: 32640948
Chen, J. B. et al. Prevalence of autoimmune disease in moyamoya disease patients in Western Chinese population. J. Neurol. Sci. 351(1–2), 184–186. https://doi.org/10.1016/j.jns.2015.02.037 (2015).
doi: 10.1016/j.jns.2015.02.037
pubmed: 25743224
Bower, R. S. et al. Moyamoya disease in a primarily white, midwestern US population: Increased prevalence of autoimmune disease. Stroke. 44(7), 1997–1999. https://doi.org/10.1161/strokeaha.111.000307 (2013).
doi: 10.1161/strokeaha.111.000307
pubmed: 23652271
Sarkar, P. & Thirumurugan, K. New insights into TNFα/PTP1B and PPARγ pathway through RNF213- a link between inflammation, obesity, insulin resistance, and Moyamoya disease. Gene. 771, 145340. https://doi.org/10.1016/j.gene.2020.145340 (2021).
doi: 10.1016/j.gene.2020.145340
pubmed: 33333224
Ito, A. et al. Enhanced post-ischemic angiogenesis in mice lacking RNF213; a susceptibility gene for moyamoya disease. Brain Res. 1594, 310–320. https://doi.org/10.1016/j.brainres.2014.11.014 (2015).
doi: 10.1016/j.brainres.2014.11.014
pubmed: 25446450
Ohkubo, K. et al. Moyamoya disease susceptibility gene RNF213 links inflammatory and angiogenic signals in endothelial cells. Sci. Rep. 5(1), 13191. https://doi.org/10.1038/srep13191 (2015).
doi: 10.1038/srep13191
pubmed: 26278786
pmcid: 4538604
Fukushima, H., Takenouchi, T. & Kosaki, K. Homozygosity for moyamoya disease risk allele leads to moyamoya disease with extracranial systemic and pulmonary vasculopathy. Am. J. Med. Genet. Part A. 170(9), 2453–2456. https://doi.org/10.1002/ajmg.a.37829 (2016).
doi: 10.1002/ajmg.a.37829
pubmed: 27375007
Chang, S. A. et al. Nonsyndromic peripheral pulmonary artery stenosis is associated with homozygosity of RNF213 p.Arg4810Lys regardless of co-occurrence of Moyamoya disease. Chest. 153(2), 404–413. https://doi.org/10.1016/j.chest.2017.09.023 (2018).
doi: 10.1016/j.chest.2017.09.023
pubmed: 28962888
Jee, T. K. et al. Prospective screening of extracranial systemic arteriopathy in young adults with Moyamoya disease. J. Am. Heart Assoc. 9(19), e016670. https://doi.org/10.1161/jaha.120.016670 (2020).
doi: 10.1161/jaha.120.016670
pubmed: 32954918
pmcid: 7792364
Ikeda, E. Systemic vascular changes in spontaneous occlusion of the circle of Willis. Stroke. 22(11), 1358–1362. https://doi.org/10.1161/01.str.22.11.1358 (1991).
doi: 10.1161/01.str.22.11.1358
pubmed: 1750042
Baek, J. W., Jo, K. I., Park, J. J., Jeon, P. & Kim, K. H. Prevalence and clinical implications of renal artery stenosis in pediatric moyamoya disease. Eur. J. Paediatric Neurol. EJPN Off. J. Eur. Paediatric Neurol. Soc. 20(1), 20–24. https://doi.org/10.1016/j.ejpn.2015.11.002 (2016).
doi: 10.1016/j.ejpn.2015.11.002
Kim, J. Y. & Cho, H. Renovascular hypertension and RNF213 p.R4810K variant in Korean children with Moyamoya disease. Clin. Nephrol. 96(2), 105–111. https://doi.org/10.5414/cn110334 (2021).
doi: 10.5414/cn110334
pubmed: 33769276
Togao, O. et al. Prevalence of stenoocclusive lesions in the renal and abdominal arteries in moyamoya disease. AJR Am. J. Roentgenol. 183(1), 119–122. https://doi.org/10.2214/ajr.183.1.1830119 (2004).
doi: 10.2214/ajr.183.1.1830119
pubmed: 15208124
Yamada, I., Himeno, Y., Matsushima, Y. & Shibuya, H. Renal artery lesions in patients with moyamoya disease: Angiographic findings. Stroke. 31(3), 733–737. https://doi.org/10.1161/01.str.31.3.733 (2000).
doi: 10.1161/01.str.31.3.733
pubmed: 10700512
Lu, M. et al. Long-term outcomes of moyamoya disease versus atherosclerosis-associated moyamoya vasculopathy using high-resolution MR vessel wall imaging. J. Neurol. Neurosurg. Psychiatry. https://doi.org/10.1136/jnnp-2022-330542 (2023).
doi: 10.1136/jnnp-2022-330542
pubmed: 37321840
Lee, J. et al. High prevalence of systemic hypertension in pediatric patients with moyamoya disease years after surgical treatment. J. Neurosurg. Pediatrics. https://doi.org/10.3171/2019.9.peds1986 (2019).
doi: 10.3171/2019.9.peds1986
Ma, Y. et al. Comparison of clinical outcomes and characteristics between patients with and without hypertension in moyamoya disease. J. Clin. Neurosci. Off. J. Neurosurg. Soc. Aust. 75, 163–167. https://doi.org/10.1016/j.jocn.2019.12.016 (2020).
doi: 10.1016/j.jocn.2019.12.016
Han, S. et al. Diabetes or calcium channel blocker contribute to cerebral hemodynamics after bypass surgery in adult patients with moyamoya disease. Quant. Imaging Med. Surg. 13(1), 293–308. https://doi.org/10.21037/qims-22-407 (2023).
doi: 10.21037/qims-22-407
pubmed: 36620177